4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Other Non-Current Liabilities data on file, last reported at $121000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 31.64% year-over-year to $121000.0 in Q1 2026; TTM through Mar 2026 was $121000.0, a 31.64% decrease from a year earlier, with the FY2025 full-year figure at $138000.0, down 28.5% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $121000.0, down from $138000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for FDMT reached as high as $369000.0 in Q4 2023 and fell as low as $12000.0 in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $134647.1 across 5 years, with a median of $138000.0 in 2025.
• Across the five-year window, Other Non-Current Liabilities sank 99.36% in 2022 and soared 1657.14% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $21000.0 in 2022, then surged by 1657.14% to $369000.0 in 2023, then tumbled by 47.7% to $193000.0 in 2024, then dropped by 28.5% to $138000.0 in 2025, then retreated by 12.32% to $121000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $121000.0 in Q1 2026, $138000.0 in Q4 2025, and $345000.0 in Q3 2025.